CREO Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): £314,500.56
Insider Selling (Last 12 Months): £1,800.12

Creo Medical Group Insider Trading History Chart

This chart shows the insider buying and selling history at Creo Medical Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Creo Medical Group Share Price & Price History

Current Price: GBX 10.22
Price Change: Price Increase of +0.14 (1.39%)
As of 12/4/2025 10:51 AM ET

This chart shows the closing price history over time for CREO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Creo Medical Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2025Craig Jonathan GullifordInsiderSell6,429GBX 14£900.06
7/22/2025Richard John ReesInsiderSell6,429GBX 14£900.06
5/30/2025Kevin CroftonInsiderBuy701,750GBX 16£112,280
1/20/2025Christopher Paul HancockInsiderBuy4,712GBX 19£895.28
1/16/2025Richard John ReesInsiderBuy4,712GBX 19£895.28
12/13/2024Kevin CroftonInsiderBuy1,179,000GBX 17£200,430
10/24/2024Richard John ReesInsiderBuy98,000GBX 20£19,600
10/21/2024Kevin CroftonInsiderBuy2,916,666GBX 24£699,999.84
1/27/2023Craig Jonathan GullifordInsiderBuy4,478GBX 20£895.60
See Full Table

SEC Filings (Institutional Ownership Changes) for Creo Medical Group (LON:CREO)

45.10% of Creo Medical Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Creo Medical Group logo
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures. For more information, please refer to the website www.creomedical.com
Read More on Creo Medical Group

Today's Range

Now: GBX 10.22
Low: 9.52
High: 10.25

50 Day Range

MA: GBX 10.99
Low: 9.90
High: 12.25

52 Week Range

Now: GBX 10.22
Low: 9.22
High: 22.50

Volume

462,745 shs

Average Volume

970,183 shs

Market Capitalization

£42.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Creo Medical Group?

Creo Medical Group's top insider shareholders include:
  1. Christopher Paul Hancock (Insider)
  2. Craig Jonathan Gulliford (Insider)
  3. Kevin Crofton (Insider)
  4. Richard John Rees (Insider)
Learn More about top insider investors at Creo Medical Group.